Cost of the Personal

While genome sequencing may enable more personalized medicine, an article in Vancouver Sun examines how it may also lead to more expensive drugs. Because therapeutics targeted against certain genetic mutations may only then be effective in a sliver of the population, Randy Shore writes in the Sun that such 'orphan drugs' could command prices ranging between $100,000 and $1 million a year for each patient.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.